DOCKET NO.: UNMC-0030 (63124US)

Application No.: 09/647,911 Office Action Dated: May 4, 2004 PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A <u>coxsackievirus</u> virus genome having a *pol* gene that encodes an RNA-dependent <u>RNA</u> polymerase, the genome being modified to produce an attenuated virus, the genome further comprising at least one *pol* gene modification that causes the polymerase to have increased fidelity as compared with a polymerase from a <u>coxsackievirus</u> virus genome that does not comprise the *pol* gene modification, wherein the increased fidelity results in a decreased reversion rate from attenuated virus to non-attenuated virus as compared with an equivalent <u>coxsackievirus</u> virus genome without the *pol* gene modification.

ication.			
2. Canceled.			
3. Canceled.			
4. Canceled.			
5. Canceled.			
6. Canceled.			
7. Canceled.			
8. Canceled.			
9. Canceled.			

DOCKET NO.: UNMC-0030 (63124US)

Application No.: 09/647,911
Office Action Dated: May 4, 2004

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

10. (Currently amended) The <u>coxsackievirus</u> virus genome of claim 1, wherein the *pol* gene modification comprises a mutation resulting in an alteration of the RNA polymerase active site.

- 11. (Currently amended) The <u>coxsackievirus virus</u> genome of claim 1, having a reversion rate at least two-fold decreased as compared with an equivalent virus without the *pol* gene modification.
- 12. (Currently amended) A viral vector for delivering a heterologous nucleic acid to a target cell, tissue or organ, comprising the <u>coxsackievirus</u> virus genome of claim 1, said genome further comprising at least one cloning site for insertion of an expressible heterologous nucleic acid.
- 13. (Original) The vector of claim 12, comprising an expressible heterologous nucleic acid encoding an antigenic molecule.
- 14. (Original) The vector of claim 12, comprising an expressible heterologous nucleic acid encoding a biologically active molecule.
- 15. (Currently amended) A live, attenuated viral vaccine comprising the <u>coxsackievirus</u> virus genome of claim 1.

Claims 16-30: Canceled.

31. (New) The coxsackievirus genome of claim 1, which is a coxsackievirus B3 genome.